- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02344355
Un essai de phase 2 sur l'ascorbate à haute dose dans le glioblastome multiforme
Ascorbate pharmacologique associé à la radiothérapie et au témozolomide dans le glioblastome multiforme : un essai de phase 2
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth). After radiation, patients receive additional cycles of temozolomide (adjuvant chemotherapy).
Participants will:
- receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase
- receive high doses of intravenous (IV) ascorbate twice a week during adjuvant chemotherapy (after radiation)
- complete health-related quality of life questionnaires pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and approximately 9 months after initiating radiation therapy.
The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Holden Comprehensive Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Ability to understand and willingness to sign informed consent (power of attorney and/or legally authorized representatives cannot sign on behalf of the patient)
- Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme.
- Diagnosis must be made by surgical biopsy or excision.
- Therapy must begin ≤ 5 weeks after surgery or biopsy
- Age ≥ 18 years
- ECOG performance status 0-2. (KPS > 50)
- Absolute neutrophil count (ANC) ≥ 1500 cells per mm3
- Platelets ≥ 100,000 per mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine ≤ 2.0 mg
- Total bilirubin ≤ 1.5 mg/dL
- ALT ≤ 3 times the institutional upper limit of normal
- AST ≤ 3 times the institutional upper limit of normal
- Tolerate one test dose (15g) of ascorbate.
- Not pregnant.
Exclusion Criteria:
- Recurrent high grade glioma
- G6PD (glucose-6-phosphate dehydrogenase) deficiency.
- Patients actively receiving insulin or using a finger-stick glucometer daily for blood glucose measurements
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.
- Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.
- Patients who are on the following drugs and cannot have a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.
- Known active concurrent malignancy, as determined by treating physicians.
- Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.
- Prior radiation therapy to the head or neck resulting in overlap of RT fields.
- Patients receiving any other investigational agents (imaging agents are acceptable)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would result in a hospital stay or delay of treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or impact patient safety.
- Pregnant women.
- Breastfeeding women.
- Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ascorbate, radiation, temozolomide
Concomitant therapy: Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions Adjuvant therapy: Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions |
oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy. Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days. For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days. If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.
Autres noms:
Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
Autres noms:
Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation. After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Survival (OS)
Délai: monthly up to 5 years post treatment
|
From radiation day 1 until date of death from any cause. |
monthly up to 5 years post treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression Free Survival (PFS)
Délai: monthly up to 5 years post treatment
|
From radiation day 1 to documented disease progression in MRI imaging as described by the RANO criteria |
monthly up to 5 years post treatment
|
|
Adverse Event Frequency
Délai: monthly through 7 months post-radiation
|
Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from radiation day 1 through 7 months post-radiation. |
monthly through 7 months post-radiation
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Health-related Quality of Life (HRQOL)
Délai: monthly for 3 months, then every 3 months up to 5 years post treatment
|
Measure health-related outcomes using the validated EORTC (European Organization for Research and Treatment of Cancer) questionnaires QLQ-C30 and BN-20. |
monthly for 3 months, then every 3 months up to 5 years post treatment
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Bryan G. Allen, MD, PhD, Assistant Professor, Department of Radiation Oncology, The University of Iowa
Publications et liens utiles
Publications générales
- Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30.
- Petronek MS, Monga V, Bodeker KL, Kwofie M, Lee CY, Mapuskar KA, Stolwijk JM, Zaher A, Wagner BA, Smith MC, Vollstedt S, Brown H, Chandler ML, Lorack AC, Wulfekuhle JS, Sarkaria JN, Flynn RT, Greenlee JDW, Howard MA, Smith BJ, Jones KA, Buettner GR, Cullen JJ, St-Aubin J, Buatti JM, Magnotta VA, Spitz DR, Allen BG. Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM. Clin Cancer Res. 2024 Jan 17;30(2):283-293. doi: 10.1158/1078-0432.CCR-22-3952.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Astrocytome
- Gliome
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Glioblastome
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Thérapeutique
- Azoles
- Glucides
- Acides sucre
- Acides, acyclique
- Acides carboxyliques
- Acides hydroxy
- Dacarbazine
- Triazènes
- Imidazoles
- Témozolomide
- Acide ascorbique
- Radiothérapie
Autres numéros d'identification d'étude
- 201504786
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.
Délai de partage IPD
Study protocol and informed consent will be shared after primary completion. Statistical analysis plan will be shared with results reporting.
Critères d'accès au partage IPD
An IRB-stamped signed usage agreement will be required in addition to a data sharing agreement between the academic centers.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .